Obesity prevalence seems to have plateaued at ~40% (refs. 1,2), suggesting that environmental penetrance (such as a hypercaloric diet or a sedentary lifestyle) is limited to a subpopulation of individuals who are genetically susceptible to obesity. Indeed, a substantial and stable proportion of the population has remained non-obese despite the modern obesogenic onslaught 3 . Determining the genetic basis for this resilience may illuminate novel intervention strategies for obesity and its associated cardiometabolic diseases. To discover novel genes that contribute to healthy low adiposity, we used a unique polygenic lean mouse line that was generated through selection for low adiposity over 60 generations. Lean mice (in which 4% of body weight is fat mass) show metabolically healthy leanness 4 , not lipodystrophy. The major quantitative trait loci (QTL) underlying divergent adiposity between lean mice and their counter-selected 'fat' mouse line (in which 23% of body weight is fat mass) have been described 5,6 , which facilitated our search for positional candidate lean genes. Direct experimental evidence 7 and QTL mapping also ruled out genes in known brainregulated appetite and energy expenditure systems-such as leptin (Lep), leptin receptor (Lepr), neuropeptide Y (Npy) and melanocortin 4 receptor (Mc4r)-as drivers of adiposity divergence. Lean mice thus allow for insight into the genetic landscape of healthy leanness that is likely manifested through peripheral mechanisms. We reasoned that selection on adiposity divergence, independently of lean mass, would enrich for genes with direct actions in the adipose tissue. To identify adipose-tissue-specific candidate lean genes, strict inclusion criteria were applied to transcriptomic profiles from three distinct white
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RESULTS
Elevated adipose Tst expression links leanness and metabolic health To prioritize positional candidate lean genes from within major adiposity QTLs 5,6 , we selected mRNAs whose levels were increased specifically in the WAT of lean mice 8 . To be considered a candidate gene, mRNA levels had to be >2-fold higher in all three WAT depotsbut comparable in the liver, muscle and kidney-of lean versus fat mice. In an independent microarray experiment, we validated that there were higher levels of Tst mRNA in the subcutaneous WAT of lean versus fat mice. Eleven genes fulfilled the tissue-specific expression criteria (expressed sequence tag (EST) AI427515, Csprs, Cyp2e1, Fv1, Ms4a4c, Ms4a6c, Pik3cg, Pon1, Rassf6, Sah and Tst), and two genes fulfilled the QTL inclusion criteria (Pik3cg on chromosome 12 and Tst on chromosome 15). Pik3cg failed validation in the independent microarray experiment. Only the nuclear-encoded Tst gene, which is positioned on chromosome 15 (78,399,556-78,405,859) within the F-line obesity QTL 3 (Fob3) 5, 6 , fulfilled all of our inclusion criteria. Tst mRNA was ~7-fold higher across the three WAT depots in lean versus fat mice (Fig. 1a) .
To support causality-and not just a simple association-with leanness, we sought evidence that increased Tst mRNA originated from a cis-acting effect within the QTL. To this end we used congenic lines of mice that had increasingly refined lean-line Fob3 QTL chromosome 15 segments around the Tst locus introgressed into an otherwise fat-line genetic background (lines U12, M and M2). The U12 line carries a ~35-Mbp QTL (Fob3b) that accounted for a 20% reduction in adiposity of the fat mouse line 5 . The M line carries a ~6.8-Mbp sub-QTL (Fob3b2) 6 that accounted for an 8.1% reduction in the adiposity of the fat mice ( Supplementary Table 1a ). The M2 line was developed specifically for this study and carries a ~2. 8 (i) Correlation of Tst mRNA levels (as determined by RNA-seq of SC fat tissue) with female adiposity in founder DO strains (n = 6 mice per strain; mice were either on a control diet or a HFD. Box plots with dashed bars correspond to minimum and maximum values. Upper and lower borders of the box correspond to the 25th and 75th percentile, respectively). (j) Representative western blot (top) and quantification (bottom) of TST expression in the SC fat of C57BL/6J mice that were fed a control diet (6J; black bar; n = 6) or a HFD (6JHFD; n = 6) for 16 weeks or of 10-week-old C57BL/6J (6J; light gray bar, n = 6) and leptin-deficient (Lep ob ) (n = 5) mice that were both fed a control diet. In a,b,d,j, data are mean ± s.e.m. In b, † † P < 0.01 versus F mice, and § § P < 0.01 versus L mice, by one-way analysis of variance (ANOVA). In d,j, **P < 0.01 (effect of diet), and † † P < 0.01 and † † † P < 0.001 (effect of line or genotype), by two-way ANOVA.
npg sub-sub-QTL (Fob3b2-M2; Supplementary Fig. 1 ) that accounted for an 8.4% reduction in the adiposity of fat mice ( Supplementary  Table 1a ). Comparable amounts of fat reduction in the M2 versus the M line suggested that the leanness effect was fully captured by the smallest (sub-sub-QTL) genetic interval ( Supplementary Fig. 1b-e and Supplementary Table 1b ). Tst mRNA levels in adipose tissue were higher in all three congenic lines than in the parental fat line, supporting Tst as a positional candidate lean gene ( Fig. 1b) . Furthermore, in Fob3b2-M2 heterozygotes, expression of the Tst allele originating from lean mice was higher than expression of the allele originating from fat mice ( Supplementary Fig. 1f,g) . Given that the Fob3b2-M2 congenic line carries a ~2.8-Mbp lean-line segment around Tst, these allele-dosage studies implicate a cis-mediated mechanism underlying increased levels of Tst mRNA in lean mice ( Supplementary Fig. 1f,g) . Co-segregation of metabolic protection with the lean-line Tst allele was confirmed in Fob3b2-M2 mice ( Supplementary Fig. 1h,i) . We used haplotype analysis of the M2 interval to restrict for causal genomic regions (which were non-identical by descent). 20 of 90 genes remained positional candidates, of which only Tst showed coordinate upregulation in all three WAT depots from the lean mice ( Fig. 1a ) and in WAT from the Fob3b2-M2 leanallele homozygotes that were generated from an F 2 cross with mice from the fat line ( Supplementary Fig. 2 ). Tst also scored as the top functional and positional candidate gene by bioinformatics approaches (Supplementary Fig. 2) .
Given the strong genetic evidence for Tst as a causal lean gene, we considered the mechanistic rationale for its effects. TST was identified more than 80 years ago as a rhodanese enzyme activity involved in cyanide detoxification 9 , with the clinical antidote thiosulfate (S 2 O 3 ) serving as a TST substrate for sulfane-sulfur transfer 9,10 . This did not immediately suggest a purpose for TST in fat cell function or adiposity. TST was, however, linked to the modulation of iron-sulfur (Fe-S) clusters and regulatory cysteine residues in succinate dehydrogenase 11 and to the modulation of NADH dehydrogenase 12 , two key mitochondrial respiratory complexes. In addition, TST degraded reactive oxygen species (ROS) with thioredoxin in cell-free systems 13 and participated in sulfide (H 2 S) metabolism 14 through its interaction with the sulfur dioxygenase ETHE1 (ref. 15) . Unfolded TST may also chaperone cytosolic 5S rRNA to the mitochondria 16 . Because mitochondrial ROS [17] [18] [19] , and more recently H 2 S 20,21 , have been implicated in adipocyte function, we hypothesized that elevated TST activity beneficially alters these pathways ( Fig. 1c) .
During the process of validating the candidate lean genes, we found that adipose TST was unexpectedly upregulated in lean mice that were challenged with a high-fat diet (HFD) ( Fig. 1d) . Moreover, the lean mice on the HFD notably lost fat mass ( Supplementary Table 2a ,b). We had reported earlier 4 that lean mice on a HFD showed fat loss in a manner that could not be fully explained on the basis of divergent eating or running behavior 7, 22 , which supported the idea of alternative mechanisms of leanness. By contrast, adipose TST levels were reduced npg in fat mice ( Fig. 1d ) that gained fat mass after being fed a HFD (Supplementary Table 2 ). We then investigated whether TST was broadly related to adiposity in mice. Tst mRNA levels in adipose tissue correlated negatively with fat mass and plasma glucose levels ( Fig. 1e,f ) but positively with adiponectin (Adipoq) mRNA across 23 commonly used mouse strains ( Fig. 1g ). RNA sequencing (RNA-seq) data from the Diversity Outbred (DO) panel of mice 23 revealed an expression QTL (eQTL) at the Tst locus, whereby Tst intervals derived from lean founder mouse strains had higher liver Tst mRNA levels ( Fig. 1h ). Higher levels of adipose Tst mRNA were also found in representative lean DO founder strains, as compared to those in obesity-susceptible strains ( Fig. 1i and Supplementary Fig. 3a ). Levels of adipose Tst mRNA ( Supplementary  Fig. 3b ,c) and TST protein ( Fig. 1j) were markedly lower in HFD-fed obesity-prone male C57BL/6J mice and in leptin-deficient, C57BL/ 6JLep ob/ob mice than in their age-matched C57BL/6J controls.
Overexpression of Tst in adipocytes preserves metabolic health
We next tested the hypothesis that elevated adipose Tst was causal for leanness. We first established that Tst was expressed predominantly in mature 3T3-L1 ( Fig. 2a ) and primary adipocytes ( Fig. 2b) . We then generated mice overexpressing Tst ~2-fold in the mature adipocytes ( Fig. 2c ) by using the adiponectin promoter 24 (which we refer to as Adipoq-Tst mice). Tst mRNA was unchanged in brown adipose tissue (BAT) or bone of Adipoq-Tst mice ( Supplementary Fig. 4a,b) . Adipoq-Tst mice were of initially comparable weight to their nontransgenic littermates ( Fig. 2d ), but they resisted HFD-induced obesity (Fig. 2d,e and Supplementary Fig. 4c,d ) and had smaller fat cells ( Fig. 2f) , despite similar food intake ( Supplementary Fig. 4e ). As compared to C57BL/6N control mice, Adipoq-Tst mice showed higher energy expenditure when fed chow or a HFD ( Supplementary Fig. 4f,g) , with a lower respiratory exchange ratio after being fed a HFD-which is indicative of preferential fat oxidation ( Fig. 2g and Supplementary  Fig. 4g )-particularly mid-way through the diurnal cycle ( Fig. 2g) .
Physical activity was comparable between mice of the two genotypes ( Supplementary Fig. 4h ). Overexpression of Tst did not increase the mRNA levels of uncoupling protein 1 (mitochondrial, proton carrier) (Ucp1) in the BAT or WAT ( Supplementary Fig. 4i ,j), suggesting that WAT beigeing is not a major driver of obesity resistance in Adipoq-Tst mice. Instead, Tst overexpression in adipocytes was associated with elevated basal mRNA levels of liver carnitine palmitoyltransferase 1a (Cpt1a) ( Fig. 2h) , a key enzyme of fatty acid oxidation, and this was corroborated by increased hepatic fat oxidation in Adipoq-Tst mice as compared to that in littermate control mice ( Fig. 2i) . We next investigated whether adipocyte Tst overexpression improved metabolic status. Adiponectin concentrations were higher in Adipoq-Tst mice than in nontransgenic littermate controls ( Fig. 3a) , consistent with elevated hepatic fat oxidation and an antidiabetic phenotype 25 . As compared to C57BL/6N mice, Adipoq-Tst mice showed mildly improved glucose homeostasis when fed a control diet ( Supplementary Fig. 5a,b) , and they were markedly protected from impaired glucose homeostasis after 6 weeks on a HFD ( Supplementary  Fig. 5c,d) . In support of the idea of preserved metabolic health, even before body-weight differences became apparent ( Fig. 2d) , euglycemic clamp experiments revealed greater whole-body insulin sensitivity ( Fig. 3b and Supplementary Table 3 ) and glucose uptake in the muscle and adipose tissue of Adipoq-Tst mice ( Fig. 3c) , as compared to those in C57BL/6N mice, after 2 weeks on a HFD. Adipose tissue from Adipoq-Tst mice had higher levels of solute carrier family (facilitated glucose transporter), member 4 (Slc2a4; also known as Glut4) mRNA (Supplementary Fig. 5e ) and GLUT4 protein ( Fig. 3d) , npg an important insulin-regulated facilitative glucose transporter. This supported the idea of insulin sensitization in primary adipose tissue as key to whole-body insulin sensitization 26 . In further support of this hypothesis, we found reduced levels of phosphorylated protein kinase B (pAKT) in the adipose tissue of C57BL/6N littermates but not in that of Adipoq-Tst mice that were on a HFD for 6 weeks ( Fig. 3e) .
Additionally, we observed that endogenous insulin suppressed free fatty acid (NEFA) release to a greater extent in Adipoq-Tst mice in vivo (Supplementary Fig. 5f ). Indices of lipolytic capacity (such as mRNA levels of adrenergic receptor, beta 3 (Adrb3)) were suppressed by a HFD in C57BL/6N littermates but not in Adipoq-Tst mice ( Fig. 3f) . Indeed, Adipoq-Tst mice that were maintained on a HFD showed basally lower amounts of phosphorylated hormone-sensitive lipase (HSL; encoded by Lipe; antibody detects phosphorylation on Ser660), whereas C57BL/6N littermates showed a distinct suppression of pHSL S660 levels after 6 weeks on a HFD (Fig. 3g ). We found a selective reduction in levels of the key triglyceride lipase patatin-like phospholipase domain containing 2 (PNPLA2; also known as ATGL)) in the adipose tissue of Adipoq-Tst mice but not in the adipose tissue of control mice that were on a HFD (Fig. 3h) . We observed a similar response for peripilin 1 (PLIN1) in HFD-fed C57BL/6N and Adipoq-Tst mice (Supplementary Fig. 5g ). To directly test whether lipolytic capacity was altered in vivo, we administered the β3 agonist CL316,243 (CL) to both groups of mice and found that Adipoq-Tst mice had enhanced NEFA release ( Fig. 3i) . Furthermore, adipocytes from Adipoq-Tst mice (basal, Adipoq-Tst versus C57BL/6N: 16 ± 4 versus 27 ± 3 pmol per min per 10 3 adipocytes, respectively; n = 6 mice per group) showed enhanced responsiveness to CL treatment (Adipoq-Tst versus C57BL/6N: +171 ± 20 versus +141 ± 13 pmol per min per 10 3 adipocytes, respectively; n = 6 mice per group; P < 0.01) and pronounced suppression of CL-induced lipolysis in response to treatment with 0.5 nM insulin (CL + insulin, Adipoq-Tst versus C57BL/6N: −126 ± 16 versus −82 ± 8 pmol per min per 10 3 adipocytes; n = 6 mice per group; P < 0.01, data are mean ± s.e.m., by two-way analysis of variance (ANOVA)) in vitro.
Tst deficiency and TST activation have reciprocal metabolic effects
We then determined whether loss of Tst gene function, as shown by a complete loss of TST enzyme activity ( Supplementary Fig. 5h ), was causal for obesity or diabetes. After 6 weeks on a HFD, Tst −/− mice had comparable gross body weight, energy expenditure and fat mass to C57BL/6N littermates (Fig. 4a,b and Supplementary  Fig. 5i ). Nevertheless, histologically, HFD-fed Tst −/− mice showed mild adipocyte hypertrophy in vivo (Fig. 4c) . To explore this further, we differentiated adipose stromal vascular cells (SVFs) in vitro and found that SVFs from Tst −/− mice had greater amounts of late-stage lipid accumulation than SVFs from C57BL/6N mice (day 9; Fig. 4d ), coincident with Tst expression in late adipogenesis ( Fig. 2a,b) . Transcriptional regulators of early preadipocyte differentiation were comparable between SVFs from mice of the different genotypes ( Supplementary Fig. 5j ). Despite comparable adiposity glucose intolerance was observed in Tst −/− mice, and this was exacerbated with a HFD as compared to that in C57BL/6N mice (Fig. 4e) . The glucose tolerance test (GTT) also revealed impaired NEFA suppression in Tst −/− mice on a HFD, as compared to that in C57BL/6N mice, despite comparable endogenous insulin output ( Fig. 4e) , an indicator of adipose insulin resistance that was confirmed in primary adipocytes from Tst −/− mice in vitro (Fig. 4f) . npg Therapeutic potential was assessed by treatment with the TST substrate thiosulfate 10, 27 , which ameliorated HFD-induced glucose intolerance in C57BL/6N, but not Tst −/− , mice ( Fig. 4g ) and modestly reduced weight gain without altered fecal fat excretion ( Supplementary  Fig. 6a,d) . We then showed that thiosulfate treatment markedly ameliorated the existing polydipsia, polyuria ( Fig. 4h) , insulin-resistance ( Fig. 4i ; glucose decrement at 60 min as a percentage of the 30-min value after 2 mU per g body weight (mU/g) humulin S: water-treated, −21 ± 4%; thiosulfate-treated, −35 ± 4%; P < 0.05 by t-test) and an elevated glycosylated hemoglobin A1c content (%HbA1c) in C57BL/KsJ-Lep db/db mice with diabetes ( Fig. 4j) , but treatment with thiosulfate did not alter body weight or fat mass ( Supplementary Fig. 6e,f) .
TST affects multiple mitochondrial pathways
We next sought evidence for mitochondrial processes that could support a beneficial metabolic effect of elevated amounts of TST ( Fig. 1c) . Adipose tissue from Adipoq-Tst mice had higher protein levels for the iron-sulfur (Fe-S)-containing succinate dehydrogenase (SDH) B subunit ( Supplementary Fig. 7a ). Higher amounts of SDHB protein were maintained in the adipose tissue of Adipoq-Tst mice but not C57BL/6N mice that were on a HFD (Fig. 5a ). Mitochondrial aconitase 2 (ACO2) and cytosolic ACO1 (Supplementary Fig. 7a-c Fig. 7d ), and it tended to suppress pyruvate and malate (complex I, NADH dehydrogenase) metabolism but augment succinate metabolism (Fig. 5b) . In contrast, treatment with the TST inhibitor 2-propenyl thiosulfate (2-PTS) 28 abolished succinate metabolism (Fig. 5b) .
We found that, for mice on a HFD, protein levels of mitochondrial superoxide dismutase 2 (SOD2) and mRNA levels of peroxiredoxin 3 (Prdx3) were higher in adipose tissue from Adipoq-Tst mice than in adipose tissue from C57BL/6N littermates ( Fig. 5c,d) , with no difference in the amount of cytosolic SOD1 (Supplementary Fig. 7e ), which was indicative of TST interactions with mitochondrial reactive oxygen species (ROS). In support of a functional role of TST on ROS, knockdown of Tst (using a lentiviral-encoded Tst-specific shRNA) ( Supplementary  Fig. 7f ) engendered higher levels of mitochondrial ROS after cells were exposed to oxidative stress ( Fig. 5e) . Moreover, ROS-sensitive 17, 19, 29 adiponectin release from 3T3-L1 adipocytes was reduced by inhibition of TST activity with 2-PTS treatment ( Supplementary Fig. 7g ) (basal versus 10 µM 2-PTS treatment: 40 ± 1 ng/ml versus 25 ± 1 ng/ml, respectively; n = 3 replicates; P < 0.01), whereas adiponectin release was increased after treatment with thiosulfate ( Fig. 5f) . Finally, a functional role for TST in H 2 S metabolism was established because isolated mitochondria from Tst −/− mice showed greater sensitivity to sulfide-mediated suppression of succinate respiration ( Fig. 5g) and because blood sulfide levels were markedly higher in Tst −/− than in C57BL/6N mice in vivo (Fig. 5h) . Dose-dependent sulfide suppression of 3T3-L1 adipocyte lipolysis ( Fig. 5i ) and reduced basal lipolysis in adipocytes from Tst −/− mice in vitro (Fig. 5j ) supported a role for TST modulation of H 2 S effects on adipocyte function.
Parallels for TST biology in humans
In support of a conservation of function for TST in humans, we found that levels of TST mRNA were higher in adipose tissue from lean subjects than in adipose tissue from subjects who were obese (Fig. 6a ) . Moreover, in a Spanish cohort 31 , the adipose tissue of subjects who were obese and had type 2 diabetes (T2D) had lower levels of TST mRNA than subjects who were not obese and who did not have T2D; TST mRNA levels thus correlated negatively with BMI ( Fig. 6b-d and Supplementary Table 4 ). TST mRNA levels in adipose tissue correlated positively with levels of GLUT4, insulin substrate receptor 1 (IRS1) and peroxisome proliferator activated receptor gamma (PPARG) mRNA ( Fig. 6e-g and Supplementary  Table 4 ), independently of BMI after adjusting with multivariate linear regression (GLUT4, P < 0.001; IRS1, P < 0.006; PPARG, P < 0.001).
TST mRNA levels also correlated with markers of lipolytic capacity and lipid droplet formation (Supplementary Fig. 8) .
The TST mRNA levels were higher in differentiated human primary fat cells ( Fig. 6h) and in differentiated human SGBS 32 clonal adipocytes than in preadipocytes (Fig. 6i) . Similarly to that observed with rodent adipocytes (Fig. 5f) , thiosulfate treatment increased adiponectin release from human SGBS adipocytes (Fig. 6j) .
DISCUSSION
Genetic mechanisms that maintain metabolic health and counter excess adiposity have received less attention than those associated with obesity. One example is polymorphisms at the MC4R locus that are associated with protection against obesity 33 . MC4R variants reflected a generality borne from early-obesity genome-wide association studies (GWAS) that emphasize the predominance of brainregulated appetite and energy expenditure pathways in explaining adiposity levels in the population [33] [34] [35] . Later GWAS that used techniques to more accurately measure fat mass, such as dual energy X-ray absorptiometry (DEXA), revealed a new class of genes with direct functions in the adipose tissue 35, 36 . Variation at the IRS1 locus [35] [36] [37] revealed an adipose mechanism that linked reduced peripheral fat deposition with impaired metabolic health 35 . From this we hypothesized the existence of adipose-specific mechanisms driving obesity resistance. However, dedicated GWAS in extremely lean, but healthy, humans that targets a population distinct from those with lipodystrophy 38 or failure-to-thrive 39 syndromes had not been reported. To gain insight into this elusive genetic category of healthy lean individuals and to focus on mechanisms in adipose tissues, we exploited the polygenic lean line of mice [4] [5] [6] [7] [8] 22 . Polygenic lean and fat lines resemble the genetic architecture of common human adiposity and do not derive from single adiposity genes with very large effect sizes [4] [5] [6] [7] [8] (such as leptin 40 ), thereby improving our chances of finding novel adiposity genes. Moreover, because lean mice were selected for extremely low adiposity but maintained lean mass, they are distinct from models that are selected for obesity studies (relative to a control line) or from those that are selected on overall body weight with adiposity as a correlated trait 41 . This may explain why the M2 sub-sub-congenic effect size is relatively large for a QTL study of a polygenic trait, supporting a prominent role for Tst as a causal leanness gene in the lean line of mice.
Compensatory alleles in the obesity-susceptible C57BL/6N genetic background that were chosen to model transgenic adipose Tst overexpression may explain the absence of gross baseline leanness in Adipoq-Tst mice. However, the effect size of obesity resistance in HFD-fed Adipoq-Tst transgenic mice supports higher Tst levels as an anti-obesity and antidiabetic mechanism. The Tst effect size is also large as compared to human adiposity GWAS hits; the fat mass and obesity associated (FTO) and iroquois homeobox 3 (IRX3) 34 locus has −0.33% body fat per effect allele 35 . Greater genetic and environmental heterogeneity in human populations is a probable explanation for this. Nevertheless, the Tst allele effect has allowed us npg to identify a novel driver for reduced adiposity and improved metabolic health in lean mice that has functional parallels in other mouse strains and in humans. Conserved regulation across states of adiposity and metabolic health indicate dynamic expression control by varied mechanisms. Furthermore, although common variant human adiposity GWAS have not identified hits at the TST locus, we may infer biological significance from our observed parallels in human TST expression and function. The Tst effect is a metabolically protective reduction of fat mass across all depots in mice. TST mRNA levels are comparable in subcutaneous and visceral fat in humans, suggesting protection in both depots.
Obesity resistance to a HFD does not involve WAT beigeing 42, 43 in lean 8 or Adipoq-Tst mice. Indeed, fat mice on a HFD showed WAT beigeing, which failed to prevent exaggerated obesity 8 . Consistent with novel WAT-derived leanness mechanisms in lean mice, beigeing genes (such as Ppargc1 and Ucp1) do not map to the major adiposity QTLs 5,6 . Such alternative mechanisms have a precedent, with some parallels and distinctions, as compared to increases in Tst levels. An adipocyte-specific knockout of the gene encoding the mitochondrial transcription factor TFAM (F-TFKO) caused a loss of complex I proteins, a compensatory increase of nuclear-encoded SDH activity and increased adipose and whole-body energy expenditure, without canonical beigeing 17 . Notably, F-TFKO mice showed a confounding increase of mitochondrial ROS with lower adiponectin release 17 , whereas elevated TST levels may quench ROS and increase adiponectin levels. In contrast, adipocyte-specific overexpression of the outer mitochondrial membrane iron-transport-inhibiting protein mitoNEET caused pronounced obesity but with elevated adiponectin-associated lipogenic WAT expansion and reduced mitochondrial ROS 19 . TST-mediated leanness presumably derives from altered mitochondrial substrate preference combined with effective ROS and H 2 S quenching, which maintains insulin sensitization in adipose tissue, lipolytic responsiveness and adiponectin release that ultimately drives peripheral oxidative disposal of excess fat.
Thiosulfate, a TST activator, is involved in cyanide detoxification 10 , and oral thiosulfate administration has been found to ameliorate heart failure in mice 27 . Thiosulfate treatment ameliorated diabetes but did not consistently reduce fat mass, suggesting that TST activation is predominantly involved in an antidiabetic mechanism. This is supported by our findings that transgenic manipulation of Tst predominantly affected glucose homeostasis rather than fat mass per se and that human TST is associated with metabolic status after adjustment for BMI. An increase in TST protein levels may have broader beneficial effects that are not recapitulated by increasing the availability of a single substrate. It is also possible that thiosulfate efficacy was limited by low oral bioavailability and the additional confounder of low target adipose TST that is found in obese mice. Notably, millimolar concentrations of thiosulfate were needed to elicit beneficial effects in vitro and in vivo. Similar compound ranges have been noted for other antidiabetic drugs, including salicylate 44 and metformin 45 . The development of TST activators that are more efficacious and have higher specificity is needed to realize the therapeutic potential of this novel antidiabetic target.
METhODS
Methods and any associated references are available in the online version of the paper. Accession codes. ArrayExpress: microarray data for the fat and lean mice can be found under accession code E-MEXP-3094.
Gene Expression Omnibus: the RNA-seq data for the DO mouse livers and the founder strain adipose tissue can be found under accession codes GSE45684 and GSE80162, respectively. 
ONLINE METhODS
Experimental animals. All experiments were performed according to guidelines set out by the ethical committees of The University of Edinburgh, The University of Cambridge or the University of Ljubljana, and they were carried out within the framework of the Animals (Scientific Procedures) Act (1986) of the United Kingdom Home Office or related laws from the European Union (Slovenia).
In all studies, animals within genotype cohorts were randomly assigned to diet or intervention groups. All animals were maintained in standard housing with 12-h light and 12-h dark cycles (7 a.m. to 7 p.m.) and ad libitum access to the appropriate diet. For in vivo experiments (for example, GTT, insulin tolerance test (ITT), euglycemic clamps and CL injections), operators and animal handlers were blinded to the data, which was generated by a second individual who was blinded to the treatment regimen until the code was broken. All of the studies, with the exception of the F 2 crosses of the M and M2 lines with the parental F lines and the RNA-seq analyses of adipose tissue from founder strains (described below), exclusively used male mice to avoid confounding effects of the female hormonal cycle. Male C57BL/6J, C57BL/6N (also referred to as 6N), C57BL/6J lep/lep (Lep ob , 10 weeks old) and C57BL/Ksj lepr/lepr (~8 weeks old) were purchased from certified distributors (Charles River Laboratories or Harlan (UK)). C57BL/Ksj lepr/lepr mice were housed in groups of three and were subsequently housed individually 3 d before ITT was performed, to determine water intake by weighing the water bottle daily and using the result from the third day as representative of stable intake. Tst −/− mice were generated by the University of California at Davis (UCD) knockout-mouse project (https://www.komp.org/ geneinfo.php?geneid=85272; project VG13928; model Tst tm1(KOMP)Vlcg , representing a definitive null allele). Sperm from viable heterozygote mice were used to fertilize C57BL/6N embryos at the University of Edinburgh Genetic Intervention and Screening technologies (GIST) facility. Tst −/− mice and age-matched littermate controls were placed on experimental diets at approximately 5-6 weeks of age. Adipoq-Tst mice were generated by cloning the mouse Tst cDNA downstream of the adiponectin promoter 24 and micro-injecting the construct into C57BL/6J blastocysts by using standard cloning techniques (University of Turku, Finland). In general, Adipoq-Tst and age-matched control littermate mice were placed on experimental diets at approximately 5-6 weeks of age.
High-fat diets (D12331, Research Diets, New Brunswick, US) and either control low-fat high-cornstarch diets (D12328) or standard control chow were used throughout the studies.
The following studies had specific subject exclusion. In the thiosulfate treatment study, one C57BL/Ksj lepr/lepr mouse that was assigned to the control (water) group rapidly and inexplicably lost weight and was humanely culled. All of the data for this mouse were removed from the study. In the euglycemic clamp studies, one animal from each genotype (6N and Adipoq-Tst) failed to recover to pre-operation body weights, and their data was excluded from the study. In one of the high-fat diet cohorts ( Fig. 2e) comparing 6N to Adipoq-Tst mice (for organ weights), a 6N control mouse failed to gain any weight and was culled due to ill-health during the study. In the gene expression and western blot analyses reported in Figures 2e-h and 5d , prior sample analysis limited available group sizes to below the optimal n = 6 for some targets.
Fat (F) and lean (L) polygenic mouse lines.
The long-term selection and further development of the F, L and congenic lines are described elsewhere 5, 6 . Animals were fed a pelleted diet (Special Diets Services, Witham, Essex, UK) or a defined low-(11% calories as fat with sucrose; D12329) or high-fat (58% calories as fat with sucrose; D12331) diet (Research Diets, New Brunswick, New Jersey).
Experiments using the congenic mouse lines. Polygenic mouse models: from a previous F 2 cross 6 a recombinant individual within the Fob3b QTL region was used as a founder for the development of the subcongenic line M used here. A total of 11 or 12 backcrosses to the fat line, with additional markerassisted elimination of other QTL regions, were performed. An F 2 cross between mice of the fat line and the congenic line M was developed and phenotyped (M × F 2 cross). Within this M × F 2 cross (Supplementary Table 1) , another recombinant individual within the Fob3b2 QTL region was identified which carried a smaller donor segment from the lean mouse line (Supplementary Fig. 1) ; this recombinant was a founder for the development of the sub-subcongenic line M2, and a subsequent F 2 cross of this mouse with mice from the fat line (M2 × F 2 cross). Positions of the lean mouse donor segments in the congenic lines were defined based on high-density single-nucleotide polymorphism (SNP) genotyping (Supplementary Fig. 1) . For all experiments, food chow (1324 maintenance diet, Altromin, Germany) and acidified water were offered ad libitum, except for mice of the M2 × F 2 cross, in which a high-fat diet (HFD; Research Diets, USA, D12108) was used. 3-week-old M2 × F 2 mice were adjusted to the HFD for 2 weeks and were maintained on it for additional 11 weeks. All of the procedures involving animals were performed according to local ethical and regulatory guidelines, which are all in compliance with the EU regulations regarding research on experimental animals (project license number 34401-3/2007/4). All of the mice were weaned at 3 weeks of age and were group-housed (four mice per cage) in individual ventilated cages (Techniplast Inc., Italy) in a controlled environment (temperature 21 °C, humidity 40-70%, and a 12-h light and 12-h dark cycle). Body weights were recorded at 3, 5, 6, 8, 10, 12, 14 and 16 weeks, at which point the adipose depots-abdominal (Abd), gonadal (epididymal, Epi), subcutaneous-femoral (SC) and mesenteric (MES)-were dissected. The sum of all of the weights of the collected fat depots was used to calculate the adiposity index (ADI).
Empirical distributions of collected phenotypic data suggested a normal distribution for each analyzed variable. Therefore, a statistical model (equation (1)) with multivariate normal distribution was fitted:
where y is an ny × 5 matrix of phenotypic values (y) for n mice, b is the vector of location parameters for effects that differed between the data sets, s is the vector of location parameters for n s seasons of dissection defined as year-month interaction, and R = I ny × R 0 is residual covariance matrix . For F 2 congenic intercrosses ('M × F 2 ' and 'M2 × F 2 '), the vector b involved the effect of sex (males and females), parity (1, 2, and 3+), the number of pups per litter (1 or 2, or 3, 4, 5, 6 and 7+), line (M and M2), and genotype within line (homozygotes fat/fat, fat/M and M/M, and heterozygotes fat/M or fat/M2). For the latter, the additive and dominance effect was tested using the deviance information criterion (DIC) statistic, which revealed that the dominance model had a better fit than the additive model. Posterior distributions were summarized with mean and s.d. for each line or genotype, as evaluated at the first parity and five pups in the litter. Posterior probabilities that the congenic lines or homozygous genotypes from F 2 congenic intercrosses differ were computed. High probability, for example, 0.95, would suggest a significant difference and presence of a Fob3b2 QTL effect.
Bioinformatics analysis of candidate genes in the Fob3b2 interval. Haplotype analysis was performed to identify haplotype blocks that are not identical by descent (non-IBD) (Supplementary Fig. 2) . These regions are likely to carry the causal polymorphism(s) that are responsible for the observed phenotypic difference between the three genotypic classes of congenic F 2 progeny. Comparative genomic analyses within the Fob3b2 region were performed in humans (http:// www.genome.gov/gwastudies/), cattle, pigs and chickens (http://www.genome. gov/gwastudies/). If a QTL that was associated with adiposity traits was found to overlap with a Fob3b2 Tst-containing region, then it was considered to be a hit. A set of 1,980 SNPs (JAX SNP IDs JAX00405958-JAX00407532) that were located within the Fob3b2 congenic region of the M line was used to genotype the F, L and congenic M or M2 lines. Interval-specific haplotype analysis was performed to identify haplotype blocks that were not identical by descent (non-IBD) between congenic lines. Such regions are likely to contain the causal polymorphism(s) that cause differences in phenotype between the observed lines 6 . 20 genes mapped to non-IBD regions (see section 'Custom RT-PCR array' below). A tool within the Mouse Phenome database (SNP Wizard) was used for SNP-strain comparisons. By using the Bio GPS Expression database (http:// biogps.org), genes were selected based on their expression levels in metabolic tissues in two independent microarray platforms (Affymetrix probe sets MOE430 and GNF1M). If a positional candidate gene showed an expression level three times above the median expression level in at least one of the metabolic tissues (pituitary, brain, white and brown adipose, liver, muscle, intestines stomach, pancreas or adrenal gland), then this was considered to be a hit. Molecular function annotations for the non-IBD candidates were retrieved from the Gene Ontology (1) (1) npg (GO, http://amigo.geneontology.org) database; any function that could be connected to adipose tissue biology and/or growth was considered a hit. Candidate genes were also queried for any impact on body weight, obesity, food intake or metabolism phenotypes of the knockout and transgenic models using the Mouse Genome Informatics (MGI) database (http://www.informatics.jax.org). Differential expression of all positional non-IBD candidates was verified by using two microarrays-a whole-genome expression Affymetrix Genechip 2.0 array and an Affymetrix Exon chip array-and various tissues from the F and L line mice (ref. 8 and this study (for M2 × F2 microarray)), using expression differences of ≥2-fold. Genes with the largest number of bioinformatics hits (highest-priority candidates) were also separately assayed by qRT-PCR, using the WAT of F, L and M2 line mice. The expression of all positional candidate genes within the core non-IBD region was measured in WAT using custom RT-PCR arrays (Life Technologies); details are in the section 'Custom RT-PCR array analysis' below.
Custom RT-PCR array analysis of positional candidates in the Fob3b2 segment. The expression of all positional candidate genes within the core non-IBD region was measured in WAT using custom RT-PCR arrays (Life Technologies) comparing homozygotes from the F 2 cross between mice of the M2 and fat lines. All TaqMan assays were custom ordered from Applied Biosystems (assay IDs below). Real-time PCR was performed using a standard TaqMan PCR kit protocol on an Applied Biosystems ViiA 7 Real-time PCR System. The 10-µl PCR reaction included 2 µl cDNA sample, 2× TaqMan Universal Master Mix II, 20× TaqMan Gene Expression Assay Buffer and RNase-free water. The reactions were incubated in a 384-well plate at 50 °C for 2 min, followed by polymerase activation at 95 °C for 10 min, and 40 cycles of 95 °C for 15 s and 60 °C for 1 min each. All reactions, including a no-template control, were run in duplicate. For each sample, the average C q was calculated and, by normalizing using three endogenous controls (Actb, Tbp and Gapdh), ∆C q was determined. The 2 −∆∆Cq method was used to quantify the relative change in expression of the target group (homozygous for genotype lean/lean in the Fob3b2 segment). Student's t-test analysis was performed, and differential expression of a gene between the F2 homozygote carrying two fat-line-derived alleles and homozygotes carrying two lean-line alleles was considered a hit. Probes used in the study were (gene, assay ID): Actb, Mm00607939_s1; Gapdh, Mm99999915_g1; Tbp, Mm00446971_m1; Arhgap39, Mm01197504_m1; Zfp251, Mm02342310_m1; Zfp7, Mm00524080_m1; Mb, Mm00442968_m1; Apol6, Mm03990658_m1; Rbm9, Mm00612735_m1; Apol7a, Mm01200950_m1; Apol9a, Mm04206749_ gH; Apol7b, Mm01616698_m1; Apol10a, Mm04214065_g1; Apol7c, Mm01628124_s1; Apol10b, Mm04212537_m1; Apol7e, Mm01616699_m1; Myh9, Mm01197036_m1; Pvalb, Mm00443100_m1; Ncf4, Mm00476300_m1; Csf2rb2, Mm00655763_m1; Csf2rb, Mm00655745_m1; Tst, Mm01195231_m1; and Mpst, Mm00460389_m1.
Quantification of allelic Tst mRNA expression. To examine whether the Tst allele from the lean (L) line is expressed at a higher level than that from the fat (F) line in heterozygote mice from the M2 × F 2 congenic cross, allele-specific TaqMan probes were designed at the SNP in the 3′ UTR (rs31534689). Sequences of the PCR primers were 5′-CCTGCTGTAGGTTCACCTTTTAGG-3′ (forward) and 5′-GGAGGCACCAAGAGCAATTCTAAA-3′ (reverse), and the TaqMan probes at the SNP site (underlined) were CCCTGTCAATCTCCGT (lean-allele specific) ACCCTGTCAATATCCGT (fat-allele specific). To determine the calibration curve, genomic DNA was isolated from two individuals homozygous for genotype FF and LL in the Fob3b2 segment and mixed in various molar ratios of F allele/L allele using fluorescently labeled probes with VIC fluorescent dye (http://www.genelink.com/newsite/products/mod_detail.asp?modid=63) and 6-fluorescein phosphoramidite (FAM) (VIC allele/FAM allele and dye-swapped)-8:1, 4:1, 2:1, 1:1, 1:2, 1:4 and 1:8. By calculating the log of (∆Rn FAM /∆Rn VIC ) for each mixing ratio, a standard curve, with the linear regression line equation log 2 (∆Rn FAM /∆Rn VIC ) = a + b × log 2 ( VIC allele /FAM allele), was generated. Allelespecific expression of the gene was measured on isolated RNA samples from eight heterozygotes with genetic differences in the Fob3b2 segment. Through intercepting measured fluorescence intensities on the standard curve, the allele ratio of heterozygous individuals was extrapolated, and the relative expression of lean-line allele:fat-line allele was determined (Supplementary Fig. 1f,g) .
Correlation analyses between Tst expression and other genes or phenotypes. Data sets of gene expression in adipose tissue from different mouse strains were downloaded from BioGPS (http://biogps.org/dataset/8/eqtl-adipose-moe430-v2/), and phenotype data for the same set of strains were obtained from the Mouse Phenome Database (http://phenome.jax.org/; CGDpheno1, 2009). A Pearson's correlation analysis was performed in SAS-STAT software. Strong and highly statistically significant correlations (P < 0.0001) between Tst and genes expressed in adipose tissue, and between Tst and phenotypes, are presented ( Fig. 1e-g) .
RNA sequencing analysis and eQTL mapping. Methods for RNA-seq library preparation, analysis and eQTL mapping in Diversity Outbred (DO) mice have been described in detail 46 . Briefly, liver or inguinal fat pad adipose tissue was dissected from 26-week-old DO or founder strain mice and stored in RNAlater solution (Life Technologies) at −80 °C. Total RNA was extracted using the Trizol Plus RNA extraction kit with on-column DNase digestion (Life Technologies). Indexed mRNA-seq libraries were generated from 1 µg total RNA using the TruSeq kit (Illumina), and 100-bp single-end reads were sequenced on the HiSeq 2000 sequencer (Illumina) according to Illumina protocols. Samples were multiplexed and replicated across 2-4 sequencing lanes to minimize technical variation. Raw RNA-seq fastq files and processed gene-level abundance estimates for the DO liver and founder strain adipose samples are archived at the Gene Expression Omnibus (GEO) database under the accession numbers GSE45684 and GSE80162, respectively. Individualized genome and transcriptome sequences were constructed for every DO and strain sample using Seqnature software 46 . RNA-seq reads were aligned to their respective individualized transcriptomes by using the Bowtie aligner, and gene expression was quantified from the readalignment profiles using RSEM software as described 46 . Expression quantitative trait loci (eQTLs) in the DO liver samples were identified with an additive liner regression model 46 .
Size estimation of fat cells. Fat beds were collected from mice shortly after culling them. The beds were transferred to a 4% paraformaldehyde (PFA)-based fixing solution and sent to histology for paraffin-embedding. The paraffin blocks were cut to a central core (estimated as closest to midway through the fat pad), then cut to 4-µm sections and mounted onto microscope slides for staining with haemotoxylin and eosin. Images were captured by using an Eclipse E800 camera (Nikon): QICAM Fast1394 (QImaging) supported by an automated Stage (ProScan II, PRIOR Scientific) for random selection. Images were generated using Image Pro Plus 7.0 software. Twenty high-magnification images (10× to 40×, depending on cell size) of the tissue were randomly selected using the ProScanII random-selection facility. From six individual imaged sections cut across a fat pad from a given mouse, six of the largest visible whole cells in each field of known area were selected and used to estimate the average cross-sectional area of the cells from that fat bed for each mouse, measured as µm 2 /cell (average of 36 random cell bodies).
Glucose and insulin tolerance tests, and in vivo NEFA release. Glucose tolerance was determined by oral or intraperitoneal administration of d-glucose (2 mg per g body weight (mg/g)) after a 6-h fast. Insulin tolerance was determined by intraperitoneal injection of humulin S (0.5-2.0 mU per g body weight (mU/g)) (for insulin-resistant Lepr mutants) after a 4-h fast. Lipolytic responsiveness was determined by injection of 1 µg/g CL316,243 after a 5-h fast. In all of the cases, blood was sampled before administration of the test substance (t = 0 min) and then generally at 15, 30, 60 and up to 120 min later (for GTT). Glucose was measured from a tail venesection using a hand-held glucometer (OneTouch, Lifescan, Milpitas, USA) and insulin (Crystalchem ELISA, Chicago, USA) or NEFA (Wako, Richmond VA, USA) was measured in plasma that was prepared from blood collected in EDTA-coated microtubes (Sarsted, Leicester, UK).
Euglycemic hyperinsulinemic clamps. Male C57BL/6N or Adipoq-Tst littermates were fed a high-fat diet for 2 weeks. Mice were anesthetized with isofluorane (5% induction, 2% maintenance in 2% oxygen) and a mirocrenathane cannula was implanted in the right exterior jugular vein and exteriorized at the back of the neck. Mice were injected with 0.05 mg/kg buprecare subcutaneously (buprenorphine) at the start of surgery and were given rimadyl (0.001% vol/vol) in their drinking water overnight on the first day after surgery. Clamps npg were performed 3 d after jugular cannulation. Mice were fasted overnight, and body weight, lean and fat mass were determined by time domain-nuclear magnetic resonance (TD-NMR) (Bruker LF50; http://www.bruker.com). All mice were infused for 2 h with 0.05 µCi/min D3-[ 3 H]glucose (NET331C005MC, PerkinElmer; http://www.perkinelmer.com) to assess endogenous glucose production by sampling shortly before the clamp procedure (−5 min). The clamp was started with infusion of higher-specific activity tracer (0.1 µCi/min) and a prime of insulin (humulin S; Eli Lily) at 9.0 mU per kg lean mass per min for 3 min, followed by a constant infusion of insulin at 2.5 mU per kg lean mass per min and a variable infusion of 20% glucose. Blood glucose was sampled from 20 min until 60 min to achieve a steady-state blood glucose level at ~7.6 mmol/ liter. A bolus of 10 µCi [2-14 C]deoxyglucose (NEC495001MC, PerkinElmer) was administered at 75 min, and samples were taken from the cut tail for tracer and glucose analysis at 80, 85, 90, 100, 110 and 120 min. Insulin levels were measured from basal (−5 min) and clamp (100 min) time points. Mice were euthanized with euthatal, which was administered down the cannula, and tissue (quadriceps muscle and epididymal fat) was rapidly excised. Tissues were weighed and extracted in 10 volumes of water; the phosphorylated [2-14 C]deoxyglucose was recovered using Poly-Prep columns, AG 1-X8 anion exchange columns (Bio-Rad). Tracers were used to calculate various aspects of glucose metabolism 47 . Tissue glucose clearance was (K g ) calculated by dividing the column-recovered tissue-phosphorylated [2-14 C]deoxyglucose by the area under the curve of plasma [2-14 C]deoxyglucose (trapezoidal method). K g was used to calculate a metabolic index (R g ), a measure of tissue-specific glucose uptake, and is the product of K g and the mean glucose concentration over the clamp period 47 . Plasma tracers were measured after deproteinization with Ba(OH) 2 and ZnSO 4 . Plasma glucose/tracers were measured after drying the sample and were used to calculate specific activity and rates of disposal (R d )/endogenous production (EndoR a ) 47 . The wet sample containing 3H 2 O was used to estimate glycolytic rates. Tracers were counted using Prosafe FC + High-Efficiency LSC cocktail (Meridian Biotechnologies Ltd) in a TriCarb 2100TR β-scintillation counter (PerkinElmer) with a dual 3 H/ 14 C program.
Antibodies (dilutions) used for this study. Donkey anti-goat IRDye 680RD
(1: 10,000; 926-68074), donkey anti-mouse IRDye 680RD (1: 10,000; 925-68072) and goat anti-rabbit IRDye 800CW (1: 10,000; 926-32211) were from Licor Biosciences Ltd. Goat anti-aconitase 2 (1: 10,000; Ab99467), rabbit anti-aconitase 2 (1: 50,000; Ab129069), goat anti-aconitase 1 (1: 500; Ab10694), complex II antibody Cocktail (1: 250; Ab110410), rabbit anti-Glut4 (1: 2,000; Ab654), rabbit anti-SDHB (1: 1,000; Ab84622) and rabbit anti-TST (1: 2,000; Ab60128) were from Abcam. Rabbit anti-SDHB (1: 7,000; NBP1-54154), rabbit anti-SOD2 (1; 2,000; NBP1-40422) and goat anti-SOD1 (1: 10,000; NB100-60944) were from Novus Biologicals. Rabbit polyclonal anti-TST antibody (1: 1,000; GTX 114858) was from Source Biochemicals. The activation state of HSL and other lipolytic protein levels were investigated using the lipolysis activation antibody sampler kit (Cell Signaling, cat number 8834), with dilutions according to the manufacturer's instructions.
Clonal adipocyte cell experiments. The 3T3-L1 preadipocyte cell line was obtained from the American Type Culture Collection. The Expression Arrest GIPZ lentiviral shRNAmir-mediated plasmid-based system (Open Biosystems, Epsom, UK) was used to transduce mature 3T3-L1 adipocytes (days 6-8 of differentiation) to knock down Tst (Supplementary Fig. 7f ). Mitochondrial ROS studies were performed by exposing the transduced 3T3-L1 cells to medium containing 1% H 2 O 2 for 6 h, followed by, after careful rinsing, exposure to Mitotracker Red-CM-H 2 XROS (final concentration 250 nM; M7513; Molecular Probes, Invitrogen, Paisley, UK). Probe oxidation was quantified using an M1000 fluorescence reader and Magellan software (Tecan, Reading, UK). Human Simpson-Golabi-Behemel syndrome (SGBS) 32 human clonal preadipocytes were maintained at 37 °C, 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with 10% (vol/vol) FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 33 µM biotin and 17 µM pantothenic acid, and differentiated with the addition of 0.5 mM isomethylbutylxanthine (IBMX), 0.25 µM dexamethasone, 20 nM insulin, 2 µM rosiglitazone, 0.01 mg/ml transferrin, 0.1 µM cortisol and 200 pM triiodothyronine (T3). From day 7 to day 21, cells were differentiated without IBMX and dexamethasone. Neither cell line was tested for mycoplasma during these studies.
TST gene expression during human preadipocyte differentiation. Isolated omental (Om) and subcutaneous (SC) preadipocytes (Zen-Bio Inc., Research Triangle Park, NC, USA) were cultured as previously described 31 . The differentiation was routinely monitored by measuring fatty acid synthase and adiponectin expression (FASN, Hs00188012_m1 and Adipoq, Hs00605917_m1).
Preparation of primary adipocytes and lipolysis.
Adipocytes were prepared from mice as follows. Mice were culled, and epididymal fat was removed into warmed Krebs buffer (118 mM NaCl, 5 mM KCl, 1.2 mM MgSO 4 , 10 mM NaPO 4 , pH 7.4, 1% BSA, 1 mg/ml glucose, 1.25 mM CaCl 2 ). The tissue was then cut with sharp scissors into approximately 2-to 4-mm-diameter pieces in Krebs buffer with 2 mg/ml collagenase I (Worthington Lot: 43C14114B). Fat fragments were incubated at 37 °C in a cell culture incubator for 40-50 min. The suspension was mixed by swirling every 10 min. Digestion was stopped when the majority of material was visible as dissociated adipocytes. The cell suspension was passed through a 250-µm mesh into a 50-ml Falcon tube to remove undigested material. An equal volume of experimental medium (1× DMEM, 4.5 g/liter glucose, 4 mM glutamine, 100 U/ml penicillin-streptomycin, 10% charcoal-dextran-stripped FBS) was added to the suspension, before centrifugation at room temperature for 3 min (1,500g). Adipocytes, which accumulate at the top of the suspension, were removed into 5 volumes of fresh experimental medium, using a cut 1-ml pipet tip. Adipocytes were swirled and given 5 min to settle to the top. Medium was removed from below the adipocyte layer, and another 5 volumes of medium was added. Cells were incubated for 60 min at 37 °C and 5% CO 2 . Cells were then given a third wash, and after removal of the medium, the adipocytes were added to their experimental tubes. For basal lipolysis, 35 µl of adipocytes were transferred to 300 µl experimental medium in a 500-µl microcentrifuge tube with open lids to maintain oxygenation of adipocytes. Tubes were gently shaken to mix the adipocytes before incubating them in a 37 °C incubator (5% CO 2 ). After 90 min, the tubes were gently shaken once more. The tubes were left still for 1 min to allow the adipocytes to resettle before samples were taken carefully from below the adipocyte layer with a catheter-linked microsyringe. For CL stimulation, CL316,243 was added in a volume of 15 µl of experimental medium to the adipocyte suspension, to a final concentration as indicated for each experiment. Tubes were gently shaken to mix the suspension, and tubes were returned to the incubator for 30 min. At this time, the tubes were gently shaken before taking samples of the medium. The tubes were returned to the incubator for a further 90 min. Tubes were shaken once more before final sampling, as described above.
NEFA assay. Standards and samples of 40 µl were incubated with WAKO NEFA kit with 100 µl of Reagent 1 (5 min, 37 °C) in a clear, flat-bottom plastic 96-well assay plate. 50 µl of Reagent 2 was then added, and the sample was incubated for another 5 min. Absorbance of each sample was read at 565 nm, with a background correction at 660 nm. A standard curve (which is linear between 5 µM and 250 µM) was prepared from a 1-mM reference sample (Wako).
Lipogenesis assay.
Adipocytes were prepared as for the lipolysis assay described above. Experimental medium (±insulin, ±10 µM cytochalasin B (glucose uptake inhibitor as a negative control)) was prepared by adding [ 3 H]glucose to a final concentration of 0.5 µCi/ml. The typical ratio of medium/cells was 5/1 by volume. Medium (+ [ 3 H]glucose) was added to a plastic scintillation vial, and then adipocytes were added. Cells and medium were mixed and incubated for 2 h in an incubator at 37 °C with 5% CO 2 and gentle shaking every 15 min. 6 M H 2 SO 4 (1 µl/10 µl of experimental medium) was added, and the sample was vortexed for 30 s to stop the reaction. Organic scintillant (two volumes per volume of medium) was added without mixing and left standing for >4 h to allow the lipids to diffuse into the organic scintillant layer. Incorporation into lipid was calculated using a 3 H-sensitive scintillation counter (with corrections using a no-cell blank, a cell blank and cytochalsin B ([ 3 H]glucose background)) and normalized to lipid mass, which was calculated by extraction of parallel samples in extraction solvent (4:1:1, isopropanol:heptane:1 N sulfuric acid). For each 100 -µl adipocyte suspension, 1.5 ml of water, 2.5 ml of extraction solvent and 1.5 ml of heptane were added, followed by solvent evaporation and accurate mass determination on a fine balance. 
